The Texas Tech University Health Sciences Center is offering a new treatment for patients suffering from severe chronic ...

Boobalan Pachaiyappan, an analyst from Roth MKM, has initiated a new Buy rating on Verona Pharma (VRNA).Stay Ahead of the Market:Discover ...

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

Novo Holdings, a leading life science investor, today announced that it has invested in a $200M Series A launch financing for Windward Bio. Headquartered in Switzerland, Windward Bio is a ...

For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.

If you have been diagnosed with advanced COPD or emphysema and do not smoke or are willing to quit, EBV treatment might be the right option for you. This relatively quick, non-surgical procedure ...

In acute infective exacerbation of chronic bronchitis or chronic obstructive pulmonary disease (COPD), adding erdosteine to standard treatment significantly modified the outcome by improving the ...

AerWave Medical, a leader in ultrasound-based interventional pulmonary solutions, today announced the successful completion of its first-in-human (FIH) feasibility study of its disease-modifying ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, and the American Lung ...

The outlook for end-stage COPD varies from person to person. Your outlook may depend on a number of factors, such as: Treatments for COPD can’t reverse damage that’s already been done ...